Glenmark Pharmaceuticals · NSE: GLENMARK · BSE: 532296
Q2 FY23 results · Jul–Sep 2022
Glenmark Pharmaceuticals reported revenue from operations of ₹3,375.25 crore (up 7.2% from Q2 FY22) and net profit of ₹278.67 crore (up 1.4% from Q2 FY22) for Q2 FY23 (Jul–Sep 2022), on a consolidated basis.
| Item | Q2 FY23 | Q2 FY22 | YoY | Q1 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 3,375.25 | 3,147.45 | +7.2% | 2,777.29 | +21.5% |
| Other income | 97.43 | (13.07) | Turned profit | 183.16 | −46.8% |
| Total income | 3,472.68 | 3,134.38 | +10.8% | 2,960.44 | +17.3% |
| Profit before tax | 480.21 | 384.96 | +24.7% | 408.01 | +17.7% |
| Net profit for the period | 278.67 | 274.81 | +1.4% | 211.11 | +32.0% |
| EPS, basic (₹) | 9.23 | 9.74 | −5.2% | 6.82 | +35.3% |
| Net margin (%) | 8.3 | 8.7 | 7.6 |
| Item | Q2 FY23 | Q2 FY22 | YoY | Q1 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,208.21 | 2,180.87 | +1.3% | 1,911.93 | +15.5% |
| Other income | 316.73 | 80.70 | +292.5% | 346.52 | −8.6% |
| Total income | 2,524.94 | 2,261.56 | +11.6% | 2,258.45 | +11.8% |
| Profit before tax | 600.52 | 877.61 | −31.6% | 695.55 | −13.7% |
| Net profit for the period | 423.15 | 754.26 | −43.9% | 492.58 | −14.1% |
| EPS, basic (₹) | 15.00 | 26.73 | −43.9% | 17.46 | −14.1% |
| Net margin (%) | 19.2 | 34.6 | 25.8 |
Consolidated
- Filed with BSE
- 13 Nov 2022, 12:32 IST
- Board meeting
- 11 Nov 2022
- Period
- 01 Jul 2022 to 30 Sep 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 13 Nov 2022, 12:32 IST
- Board meeting
- 11 Nov 2022
- Period
- 01 Jul 2022 to 30 Sep 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE